Trial Profile
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Bevacizumab; Carboplatin
- Indications Adenocarcinoma; Clear cell sarcoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- 23 Jun 2023 Planned End Date changed from 7 Jun 2023 to 7 Jun 2024.
- 28 Dec 2017 Planned End Date changed from 1 Dec 2014 to 6 Jun 2027.
- 07 Feb 2017 Results (n=70) of ACRIN 6695 study assessing association between CTP biomarkers and PFS-6, published in the Clinical cancer research: an official journal of the American Association for Cancer Research